Actively Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Led by ModeX Therapeutics, An OPKO Health Company · Updated on 2026-05-06
285
Participants Needed
6
Research Sites
242 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
CONDITIONS
Official Title
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be 18 years of age or older
- Confirmed diagnosis of metastatic solid tumors by tissue analysis
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- At least one measurable tumor lesion per RECIST v1.1 criteria
- Use of contraception according to local clinical study regulations for men and women
- Adequate blood, liver, and kidney function
- Able to provide signed informed consent
You will not qualify if you...
- Clinically significant heart disease
- Unresolved side effects from previous cancer treatments
- Previous solid organ or blood transplant
- Untreated, active, or uncontrolled brain metastases
- Known HIV infection, active hepatitis B or C, or uncontrolled infections requiring IV treatment
- Receipt of live-virus vaccination within 28 days before treatment start
- Deemed unsuitable for participation by the investigator due to medical or clinical reasons
- Participation in another clinical study during the treatment period
- Known allergy to MDX2001 or its ingredients
- Use of supplemental oxygen for daily activities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Sarah Cannon Research Institute
Denver, Colorado, United States, 80218
Actively Recruiting
2
Sylvester Comprehensive Cancer Center - University of Miami Health System
Miami, Florida, United States, 33136
Actively Recruiting
3
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
4
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
5
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
6
NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
E
Email recommended
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here